| |
Hepatitis B
|
Hepatitis B is one of the major diseases
of mankind and is a serious global public health problem.
It is preventable with safe and effective vaccines
that have been available since 1982. Of the 2 billion
people who have been infected with the hepatitis B
virus (HBV), more than 350 million have chronic (lifelong)
infections. These chronically infected persons are
at high risk of death from cirrhosis of the liver
and liver cancer, diseases that kill about one million
persons each year. Although the vaccine will not cure
chronic hepatitis, it is 95% effective in preventing
chronic infections from developing, and is the first
vaccine against a major human cancer.
WHAT IS HEPATITIS?
Hepatitis means inflammation of the liver, and the
most common cause is infection with one of 5 viruses,
called hepatitis A,B,C,D, and E. All of these viruses
can cause an acute disease with symptoms lasting several
weeks including yellowing of the skin and eyes (jaundice);
dark urine; extreme fatigue; nausea; vomiting and
abdominal pain. It can take several months to a year
to feel fit again. Hepatitis B virus can cause
|
|
 |
chronic infection in which the patient
never gets rid of the virus and many years later develops
cirrhosis of the liver or liver cancer. HBV is the most
serious type of viral hepatitis and the only type causing
chronic hepatitis for which a vaccine is available.
WHO GETS HEPATITIS B?
In much of the developing world, (sub-Saharan Africa, most
of Asia, and the Pacific), most people become infected with
HBV during childhood, and 8% to 10% of people in the general
population become chronically infected. In these regions
liver cancer caused by HBV figures among the first three
causes death by cancer in men.
High rates of chronic HBV infection are also found in the
Amazon and the southern parts of Eastern and Central Europe.
In the Middle East and Indian sub-continent, about 5% are
chronically infected. Infection is less common in Western
Europe and North America, where less than 1% are chronically
infected.
Young children who become infected with HBV are the most
likely to develop chronic infection. About 90% of infants
infected during the first year of life and 30% to 50% of
children infected between 1 to 4 years of age develop chronic
infection. The risk of death from HBV-related liver cancer
or cirrhosis is approximately 25% for persons who become
chronically infected during childhood.
HOW DO PEOPLE GET INFECTED ?
Hepatitis B virus is transmitted by contact with blood or
body fluids of an infected person in the same way as human
immunodeficiency virus (HIV), the virus that causes AIDS.
However, HBV is 50 to 100 times more infectious than HIV.
The main ways of getting infected with HBV are:
• Perinatal (from mother to baby at the birth)
• Child-to-child transmission
• Unsafe injections and transfusions
• Sexual contact
Worldwide, most infections occur from infected mother to
child, from child to child contact in household settings,
and from reuse of unsterilized needles and syringes. In
many developing countries, almost all children become infected
with the virus.
In many industrialized countries (e.g. Western Europe and
North America), the pattern of transmission is different.
In these countries, mother-to-infant and child-to-child
transmission accounted for up to one third of chronic infections
before childhood hepatitis B vaccination programmes were
implemented. However, the majority of infections in these
countries are acquired during young adulthood by sexual
activity, and injecting drug use. In addition, hepatitis
B virus is the major infectious occupational hazard of health
workers, and most health care workers have received hepatitis
B vaccine.
Hepatitis B virus is not spread by contaminated food or
water, and cannot be spread casually in the workplace.
CAN CHRONIC HEPATITIS B AND LIVER CANCER BE TREATED?
Liver cancer is almost always fatal, and usually develops
between 35 and 65 years of age, when people are maximally
productive and with family responsibilities. The loss of
a mother or a father in a developing country can devastate
the entire family. In developing countries, most people
with liver cancer die within months of diagnosis. In industrialized
countries, surgery and chemotherapy can prolong life up
to a few years. Chronic hepatitis B in some patients is
treated with drugs called interferon or lamivudine, which
can help some patients. However, interferon or lamivudine
therapy costs thousands of dollars and will never be available
to most patients in developing countries. Patients with
cirrhosis are sometimes given liver transplants, with varying
success. It is preferable to prevent this disease with vaccine
than to try and cure it.
SYMPTOMS AND COMPLICATIONS
Hepatitis B virus infection may either be acute (self-limited)
or chronic (long-standing). Persons with self-limited infection
clear the infection spontaneously within weeks to months.
The greater a person's age at the time of infection, the
greater the chance their body will clear the infection.
More than 95% of people who become infected as adults or
older children will stage a full recovery and develop protective
immunity to the virus. However, only 5% of new-born that
acquire the infection from their mother at birth will clear
the infection. Of those infected between the age of one
to six, 70% will clear the infection. When the infection
is not cleared, one becomes a chronic carrier of the virus.
Acute infection with hepatitis B virus is associated with
acute viral hepatitis - an illness that begins with general
ill-health, loss of appetite, nausea, vomiting, body aches,
mild fever, dark urine, and then progresses to development
of jaundice. It has also been noted that itchy skin all
over the body, has been an indication as a possible symptom
of all hepatitis virus types. The illness lasts for a few
weeks and then gradually improves in most of the affected
people. A few patients may have more severe liver disease
(fulminant hepatic failure), and may die as a result of
it. The infection may also be entirely asymptomatic and
may go unrecognized.
Chronic infection with hepatitis B virus may be either asymptomatic
or may be associated with a chronic inflammation of the
liver (chronic hepatitis), leading to cirrhosis over a period
of several years. This type of infection dramatically increases
the incidence of liver cancer. Hepatitis D infection requires
a concomitant infection with hepatitis B. Co-infection with
hepatitis D increases the risk of liver cirrhosis and subsequently,
liver cancer. |
|